• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗病毒策略在大流行和季节性流感中的应用。

Antiviral strategies for pandemic and seasonal influenza.

机构信息

NexBio, Inc./10665 Sorrento Valley Rd, San Diego, CA 92121, USA.

出版信息

Viruses. 2010 Aug;2(8):1766-1781. doi: 10.3390/v2081766. Epub 2010 Aug 20.

DOI:10.3390/v2081766
PMID:21994706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3185731/
Abstract

While vaccines are the primary public health response to seasonal and pandemic flu, short of a universal vaccine there are inherent limitations to this approach. Antiviral drugs provide valuable alternative options for treatment and prophylaxis of influenza. Here, we will review drugs and drug candidates against influenza with an emphasis on the recent progress of a host-targeting entry-blocker drug candidate, DAS181, a sialidase fusion protein.

摘要

虽然疫苗是季节性和大流行性流感的主要公共卫生应对措施，但在缺乏通用疫苗的情况下，这种方法存在固有局限性。抗病毒药物为流感的治疗和预防提供了有价值的替代选择。在这里，我们将回顾针对流感的药物和药物候选物，重点介绍最近进展迅速的一种宿主靶向进入抑制剂药物候选物 DAS181，即一种唾液酸酶融合蛋白。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fb/3185731/91000823cefc/viruses-02-01766f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fb/3185731/14c0ffd18d0e/viruses-02-01766f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fb/3185731/91bd7888d670/viruses-02-01766f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fb/3185731/91000823cefc/viruses-02-01766f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fb/3185731/14c0ffd18d0e/viruses-02-01766f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fb/3185731/91bd7888d670/viruses-02-01766f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5fb/3185731/91000823cefc/viruses-02-01766f3.jpg

相似文献

1
Antiviral strategies for pandemic and seasonal influenza.抗病毒策略在大流行和季节性流感中的应用。
Viruses. 2010 Aug;2(8):1766-1781. doi: 10.3390/v2081766. Epub 2010 Aug 20.
2
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.新型唾液酸酶融合蛋白 DAS181 抑制神经氨酸酶抑制剂耐药性流感病毒。
PLoS One. 2009 Nov 6;4(11):e7838. doi: 10.1371/journal.pone.0007838.
3
Drugs in development for influenza.正在研发中的流感药物。
Drugs. 2010 Jul 30;70(11):1349-62. doi: 10.2165/11537960-000000000-00000.
4
Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.关于使用唾液酸酶融合蛋白作为实验性药物对抗季节性流感和大流行性流感的担忧。
J Antimicrob Chemother. 2008 Aug;62(2):219-23. doi: 10.1093/jac/dkn026. Epub 2008 Jan 31.
5
Antiviral drugs in influenza: an adjunct to vaccination in some situations.流感抗病毒药物：在某些情况下作为疫苗接种的辅助手段。
Prescrire Int. 2006 Feb;15(81):21-30.
6
Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.2009年甲型H1N1流感病毒的神经氨酸酶活性及在支气管肺泡灌洗液中的抗病毒活性耐药性
J Virol. 2016 Apr 14;90(9):4637-4646. doi: 10.1128/JVI.00013-16. Print 2016 May.
7
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.新型唾液酸酶融合蛋白DAS181可保护小鼠免受致死性禽流感H5N1病毒感染。
J Infect Dis. 2007 Nov 15;196(10):1493-9. doi: 10.1086/522609. Epub 2007 Oct 31.
8
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.唾液酸酶融合蛋白作为一种新型的流感病毒感染广谱抑制剂。
Antimicrob Agents Chemother. 2006 Apr;50(4):1470-9. doi: 10.1128/AAC.50.4.1470-1479.2006.
9
Influenza antivirals and their role in pandemic preparedness.流感抗病毒药物及其在大流行准备中的作用。
Antiviral Res. 2023 Feb;210:105499. doi: 10.1016/j.antiviral.2022.105499. Epub 2022 Dec 23.
10
Antivirals in seasonal and pandemic influenza--future perspectives.季节性流感和大流行性流感中的抗病毒药物——未来展望。
Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1(Suppl 1):76-80. doi: 10.1111/irv.12049.

引用本文的文献

1
Secondary structure of the segment 5 genomic RNA of influenza A virus and its application for designing antisense oligonucleotides.流感 A 病毒 5 节基因组 RNA 的二级结构及其在反义寡核苷酸设计中的应用。
Sci Rep. 2019 Mar 7;9(1):3801. doi: 10.1038/s41598-019-40443-7.
2
Evaluation of antiviral activity of Ocimum sanctum and Acacia arabica leaves extracts against H9N2 virus using embryonated chicken egg model.采用鸡胚模型评价神圣罗勒和阿拉伯金合欢叶提取物抗 H9N2 病毒的活性。
BMC Complement Altern Med. 2018 Jun 5;18(1):174. doi: 10.1186/s12906-018-2238-1.
3
Neuraminidase-producing oral mitis group streptococci potentially contribute to influenza viral infection and reduction in antiviral efficacy of zanamivir.

本文引用的文献

1
Drugs in development for influenza.正在研发中的流感药物。
Drugs. 2010 Jul 30;70(11):1349-62. doi: 10.2165/11537960-000000000-00000.
2
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.应对大流行性流感：流感抗病毒药物和耐药性简介。
J Antimicrob Chemother. 2010 Jun;65(6):1086-93. doi: 10.1093/jac/dkq100. Epub 2010 Apr 7.
3
Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection.基于唾液酸酶的抗流感病毒疗法可预防二次肺炎链球菌感染。
产生神经氨酸酶的口腔轻链群链球菌可能会导致流感病毒感染，并降低扎那米韦的抗病毒疗效。
Cell Mol Life Sci. 2015 Jan;72(2):357-66. doi: 10.1007/s00018-014-1669-1. Epub 2014 Jul 8.
4
Influenza RNA-Dependent RNA Polymerase (RdRp) Inhibitors: Potential New Therapy for Influenza Treatment.流感病毒RNA依赖性RNA聚合酶（RdRp）抑制剂：流感治疗的潜在新疗法。
ACS Med Chem Lett. 2013 Oct 18;4(12):1133-4. doi: 10.1021/ml400411e. eCollection 2013 Dec 12.
5
Novel antiviral agents for respiratory viral infection in immunocompromised adults.免疫功能低下成人呼吸道病毒感染的新型抗病毒药物。
Curr Infect Dis Rep. 2013 Dec;15(6):497-503. doi: 10.1007/s11908-013-0370-0.
6
Model-based simulation and prediction of an antiviral strategy against influenza A infection.基于模型的模拟和预测抗甲型流感病毒感染的抗病毒策略。
PLoS One. 2013 Jul 9;8(7):e68235. doi: 10.1371/journal.pone.0068235. Print 2013.
7
Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers.通过诱导形成更高阶核蛋白寡聚物的小分子来抑制流感病毒复制。
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15366-71. doi: 10.1073/pnas.1107906108. Epub 2011 Sep 6.
J Infect Dis. 2010 Apr 1;201(7):1007-15. doi: 10.1086/651170.
4
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.T-705（法匹拉韦）对致死性 H5N1 流感 A 病毒的活性。
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):882-7. doi: 10.1073/pnas.0909603107. Epub 2009 Dec 22.
5
DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis.唾液酸酶融合蛋白 DAS181 抗流感病毒感染的体外药效学分析：保护人呼吸道上皮细胞。
J Antimicrob Chemother. 2010 Feb;65(2):275-84. doi: 10.1093/jac/dkp421. Epub 2009 Nov 26.
6
Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.法匹拉韦（T-705）与奥司他韦联合用药对小鼠流感病毒感染的影响。
Antimicrob Agents Chemother. 2010 Jan;54(1):126-33. doi: 10.1128/AAC.00933-09. Epub 2009 Nov 9.
7
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.新型唾液酸酶融合蛋白 DAS181 抑制神经氨酸酶抑制剂耐药性流感病毒。
PLoS One. 2009 Nov 6;4(11):e7838. doi: 10.1371/journal.pone.0007838.
8
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.新型甲型 H1N1 流感病毒被神经氨酸酶融合蛋白 DAS181 强力抑制。
PLoS One. 2009 Nov 6;4(11):e7788. doi: 10.1371/journal.pone.0007788.
9
The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.帕拉米韦用于治疗2009年甲型H1N1流感的紧急使用授权。
N Engl J Med. 2009 Dec 3;361(23):2204-7. doi: 10.1056/NEJMp0910479. Epub 2009 Nov 2.
10
Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.2009年北卡罗来纳州两名接受预防治疗的夏令营营员感染对奥司他韦耐药的2009年甲型H1N1大流行性流感病毒
MMWR Morb Mortal Wkly Rep. 2009 Sep 11;58(35):969-72.